Explore practical implications of new research in nephrotic syndrome, from renal biopsy and genetic testing to managing ...

Neutrophil gelatinase-associated lipocalin (NGAL), a biomarker released in response to tubular injury, may serve as a noninvasive tool for measuring kidney injury. A new systematic review and ...

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data1,2Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody ...

FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has approved Roche Holding AG’s (SIX:RO) Gazyva/Gazyvaro ...

Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study2 Lupus nephritis is a debilitating condition that ...

Eight-year-old Abhijot Singh had been suffering from a kidney disorder. His story came to light during the Punjab floods, with NDTV running a campaign to ensure the child gets the help he needed. He's ...

FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data1,2Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody t ...

Renalys Pharma reaches Japan PMDA agreement on phase III trials of sparsentan for FSGS and Alport syndrome: Tokyo, Japan Monday, October 20, 2025, 18:00 Hrs [IST] Renalys Pharma, ...

KDIGO's new IgA nephropathy guideline shifts the treatment paradigm from supportive care alone to targeting the disease's immunologic nature.

Roche RHHBY announced that the FDA has approved a regulatory filing seeking the label expansion of Gazyva/Gazyvaro ...